13 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)
Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,
Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Voir le projet
26
Participants partenaires
TERMINÉ
Improving Prostate Cancer Outcome with Vectored Vaccines (IMPROVE)
Date du début: 1 avr. 2014, Date de fin: 31 mars 2018,
A successful vaccine against cancer is most likely to work through the induction of potent CD8+ T cells that can successfully kill tumour cells. But achieving this has proved difficult and only low level responses are induced by current vaccine approaches. Nonetheless, two therapeutic immunisation strategies have shown partial success in targeting prostate cancer, and one recently reached licensur ...
Voir le projet
5
Participants partenaires
TERMINÉ
Advanced Immunization Technologies (ADITEC)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet
53
Participants partenaires
TERMINÉ
The genetic basis of meningococcal and other life threatening bacterial infections of childhood (EUCLIDS)
Date du début: 1 déc. 2011, Date de fin: 31 mai 2017,
Bacterial infection is the major cause of disability and death in children worldwide. We will use meningococcal disease (MD) as a model to understand genetic factors underlying susceptibility and severity of childhood bacterial infection which will then be applied to other childhood infections. We have established cohorts of patients with MD in Central and Southern Europe (CE,SE), UK and Africa as ...
Voir le projet
16
Participants partenaires
TERMINÉ
European Multicentre Tics in Children Studies (EMTICS)
Date du début: 1 déc. 2011, Date de fin: 31 mai 2017,
This project will undertake pre-clinical and cohort studies that address susceptibility factors for paediatric and adolescent tic disorders, with a particular focus on comorbid obsessive-compulsive symptomatology, from clinical, epidemiological, genetic, microbiological and immunological angles. EMTICS aims to elucidate the complex aetiology of the onset and clinical course of chronic tic disorder ...
Voir le projet
33
Participants partenaires
TERMINÉ
A Multi-Stage Malaria Vaccine (MultiMalVax)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,
A highly effective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. MultiMalVax will develop a highly effective multi-stage malaria vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas.Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite’s life- ...
Voir le projet
6
Participants partenaires
TERMINÉ
Host-microbe interactions in health and disease. Interface with the immune system (HOMIN)
Date du début: 1 avr. 2013, Date de fin: 31 mars 2017,
"HOMIN is designed as an advanced education and research program meant to train junior investigators possessing medical and/or scientific educational backgrounds to become future leading scientists in academic institutions, private companies, or administration.The HOMIN objectives are:1. To provide multidisciplinary and intersectorial scientific education through the study of host-microbe interact ...
Voir le projet
5
Participants partenaires
TERMINÉ
Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)
Date du début: 1 mars 2012, Date de fin: 31 déc. 2016,
BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil ...
Voir le projet
24
Participants partenaires
TERMINÉ
Training network for next generation vaccinologists (VACTRAIN)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
Vaccines are the most cost-effective health interventions available (WHO). The impact of vaccination on the health of the world’s population cannot be overstressed. Vaccinolgy is the multidisciplinary discipline of developing vaccine interventions it combines knowledge from basic sciences, medical sciences, public health and social sciences. Ideally a vaccinologists would be able to have a general ...
Voir le projet
9
Participants partenaires
TERMINÉ
Regulation of Expression of Staphylococcus aureus Vaccine Antigen Candidates (RESTAVAC)
Date du début: 1 sept. 2013, Date de fin: 31 août 2015,
Staphylococcus aureus is a commensal of the human skin and nares, and a major cause of skin, and soft tissue as well as invasive infections. Bacterial pathogenicity results from a complex interplay of virulence factors with regulatory systems that respond to multiple external signals from the host environment and the bacterial population. Currently no vaccine against S. aureus is available. Novart ...
Voir le projet
1
Participant partenaire
TERMINÉ
A Clostridal Biology Network to Facilitate European-wide Medical Countermeasures and Commercial Exploitation (CLOSTNET)
Date du début: 1 sept. 2009, Date de fin: 31 août 2013,
"There is an urgent need to better understand the basic biology of Clostridium as a prerequisite for both countering the diseases they cause (C.difficile, C.perfringens and C.botulinum), and exploiting their beneficial properties in industry (biofuels by C.acetobutylicum) and medicine (cancer therapy by C.sporogenes). Attainment of this goal is being impeded because: (i) European research efforts ...
Voir le projet
14
Participants partenaires
TERMINÉ
Impact of adjuvants on T cell differentiation after Influenza Vaccination analyzed at the Single Cell Level (TCDIFLU)
Date du début: 1 mars 2011, Date de fin: 28 févr. 2013,
"Mutating viruses and resistance to drugs are the major challenges to overcome in influenza (flu) prevention and treatment. Virus-neutralizing antibodies are the key for protection against flu infection, but flu-specific CD4+ and CD8+ T cells play a significant role by providing help to B cells and in viral clearance, respectively.There are many vaccines against flu infection approved for human us ...
Voir le projet
1
Participant partenaire
TERMINÉ
Design of a vaccine to immunize neonates against GBS infections through a durable maternal immune response (DEVANI)
Date du début: 1 janv. 2008, Date de fin: 30 juin 2011,
"Direct vaccination cannot prevent diseases that affect neonates in the first days of life. Group B Streptococcus (GBS) is the major cause of neonatal septicemia and meningitis affecting up to one in every thousand live births. Over 80% of cases occur in the first 7 days after birth and the remaining 20% of disease occurs between 8-90 days after birth. Studies carried out in the USA indicate that ...
Voir le projet